Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Martin Vogel

Showing results (111-120 of 116) with videos related to

Pageof 12
Sort By:
You have reached the last page of results.This site can display upto 116 results.
The Lancet. Haematology|January 5, 2025
Patient-reported outcomes following ciltacabtagene autoleucel or standard of care in patients with lenalidomide-refractory multiple myeloma (CARTITUDE-4): results from a randomised, open-label, phase 3 trialRoberto Mina, Anne K Mylin, Hisayuki Yokoyama, et al.
Blood|September 12, 2022
Efficacy and safety of cilta-cel in patients with progressive multiple myeloma after exposure to other BCMA-targeting agentsAdam D Cohen, María-Victoria Mateos, Yael C Cohen, et al.
Journal for Immunotherapy of Cancer|May 3, 2023
BCMA CAR-T induces complete and durable remission in refractory plasmablastic lymphomaSharmila Raghunandan, Melinda Pauly, William G Blum, et al.
The Lancet. Oncology|January 10, 2026
Cilta-cel in lenalidomide-refractory multiple myeloma (CARTITUDE-4): an updated analysis including overall survival from an open-label, multicentre, randomised, phase 3 trialHermann Einsele, Jesús San-Miguel, Binod Dhakal, et al.
Leukemia|March 25, 2022
LocoMMotion: a prospective, non-interventional, multinational study of real-life current standards of care in patients with relapsed and/or refractory multiple myelomaMaria-Victoria Mateos, Katja Weisel, Valerio De Stefano, et al.
The New England Journal of Medicine|February 12, 2025
CAR+ T-Cell Lymphoma after Cilta-cel Therapy for Relapsed or Refractory MyelomaSimon J Harrison, Cyrille Touzeau, Nicolas Kint, et al.
Pageof 12

Showing results (111-120 of 116) with videos related to

Sort By:
Pageof 12
You have reached the last page of results.This site can display upto 116 results.
The Lancet. Haematology|January 5, 2025
Patient-reported outcomes following ciltacabtagene autoleucel or standard of care in patients with lenalidomide-refractory multiple myeloma (CARTITUDE-4): results from a randomised, open-label, phase 3 trialRoberto Mina, Anne K Mylin, Hisayuki Yokoyama, et al.
Blood|September 12, 2022
Efficacy and safety of cilta-cel in patients with progressive multiple myeloma after exposure to other BCMA-targeting agentsAdam D Cohen, María-Victoria Mateos, Yael C Cohen, et al.
Journal for Immunotherapy of Cancer|May 3, 2023
BCMA CAR-T induces complete and durable remission in refractory plasmablastic lymphomaSharmila Raghunandan, Melinda Pauly, William G Blum, et al.
The Lancet. Oncology|January 10, 2026
Cilta-cel in lenalidomide-refractory multiple myeloma (CARTITUDE-4): an updated analysis including overall survival from an open-label, multicentre, randomised, phase 3 trialHermann Einsele, Jesús San-Miguel, Binod Dhakal, et al.
Leukemia|March 25, 2022
LocoMMotion: a prospective, non-interventional, multinational study of real-life current standards of care in patients with relapsed and/or refractory multiple myelomaMaria-Victoria Mateos, Katja Weisel, Valerio De Stefano, et al.
The New England Journal of Medicine|February 12, 2025
CAR+ T-Cell Lymphoma after Cilta-cel Therapy for Relapsed or Refractory MyelomaSimon J Harrison, Cyrille Touzeau, Nicolas Kint, et al.
Pageof 12